Releases
SNGXW
0.0090
0.00%
0.0000
  • All
  • Financials
  • Insiders
More
Webull provides the latest SOLIGENIX WT (SNGXW) stock and general news. This information may help you make smarter investment decisions.
About SNGXW
Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing products to treat rare diseases. The Company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. Specialized BioTherapeutics segments includes developing of SGX301 (synthetic hypericin) a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). Public Health Solutions includes RiVax to protect against exposure to ricin toxin vaccine candidate and SGX943 therapeutic candidate for antibiotic resistant and infectious disease. The Company's Development programs include innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, oral mucositis in head and neck cancer, and oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).